DelveInsight’s Natural Killer (NK)-Cell Lymphoma Pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer (NK)-Cell Lymphoma ...

The presentation will feature the design and objectives of the Phase 1 study, which marks the first clinical application of ...

Genmab A/S (Nasdaq: GMAB) announced today that it will present new research from its comprehensive development program evaluating its late-stage portfolio at the 2025 American Society of Clinical ...

Hodgkin's lymphoma and acute lymphoblastic leukemia—two types of cancer that affect blood cells—do not respond adequately to treatment with CAR-T cells. The therapy involves harvesting the patient's ...

Study in mice found transient microglial depletion, or chemokine receptor blockade, resolved immunotherapy-related cognitive impairment.

The agent could be repurposed to treat various cancer types, including leukemia, lymphoma and breast ... “It doesn’t affect the body. It affects the cells that are rapidly dividing, and ...

An additional case of indolent CD4+ cytotoxic CAR+ T-cell lymphoma in the small intestine was reported in a patient who received cilta-cel therapy; numerous genetic alterations were identified ...

2 “The inclusion of ctDNA testing in the NCCN Guidelines gives us a powerful tool to address both challenges – providing guidance when biopsy isn't possible and helping ... in Advanced-stage diffuse ...

Follicular lymphoma, an indolent lymphoma ... Lunsumio targets the CD20 cells of FL and the CD3 cells of cytotoxic T cells, offering a viable solution for individuals with multiple relapses. B-Cell ...

The most well-known type of T cell therapy is CAR-T cell therapy, which has been approved for use by the US FDA since 2017 to treat blood cancers such as acute leukaemia, lymphoma and multiple ...

Peripheral T cell lymphoma, not otherwise specified (PTCL NOS ... Chemotherapy uses anti cancer (cytotoxic) drugs to destroy cancer cells. The drugs circulate throughout the body in your bloodstream.

Indolent CD4+ cytotoxic chimeric antigen receptor (CAR) T-cell lymphoma involving the small intestine was diagnosed in a patient who had previously received ciltacabtagene autoleucel (cilta-cel ...